NCT05904132Recruiting
Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
The project is a placebo-controlled study that aims to use closed-loop transcranial alternating current stimulation (tACS) to study patients with symptoms of mild cognitive impairment which is likely due to Alzheimer's disease or another form of dementia (AD-MCI). Patients will undergo an EEG and complete some questionnaires and computer tasks during each study visit. The project has the following aims and hypotheses: 1.) To determine the impact of closed-loop 40 Hz tACS on the entrainment of natural gamma rhythms in patients with AD-MCI, 2.) To determine the impact of closed-loop 40 Hz tACS on cognitive performance in patients with AD-MCI, and 3.) To assess the relationship between baseline neurodegenerative burden and impact of tACS. \[exploratory\]
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 22 May 2023
- Start date
- 31 Jan 2025
- Primary completion date
- Jun 2027
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT05904132
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 31 Jan 2025 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute or decompensated active medical conditions, including cancer, cardiovascular disease, stroke, congestive heart failure
- Active hematological, renal, pulmonary, endocrine or hepatic disorders
- tACS contraindications (lesions in the scalp, history of seizures)
Other
- Known presence of a structural brain lesion (e.g., tumor, cortical infarct)
- Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
Who the study is looking for
- Overall cognitive functional status consistent with amnesic MCI (CDR 0.5) likely due to AD (AD biomarker supported)
- 50-80 years of age
- English native speakers
Age in the registry: 50 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Charlestown | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.